China Extends Gold Buying Streak as Reserves Surge Despite Volatile Prices 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Instagram Outage Disrupts Thousands of U.S. Users 
South Korea’s Weak Won Struggles as Retail Investors Pour Money Into U.S. Stocks 
Gold and Silver Prices Slide as Dollar Strength and Easing Tensions Weigh on Metals 
Global Markets Slide as AI, Crypto, and Precious Metals Face Heightened Volatility 
Silver Prices Plunge in Asian Trade as Dollar Strength Triggers Fresh Precious Metals Sell-Off 
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns 
Trump Signs Executive Order Threatening 25% Tariffs on Countries Trading With Iran 
Japanese Pharmaceutical Stocks Slide as TrumpRx.gov Launch Sparks Market Concerns 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Oil Prices Slip as U.S.–Iran Talks Ease Supply Disruption Fears 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Asian Markets Slip as AI Spending Fears Shake Tech, Wall Street Futures Rebound 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Celltrion Inc., a biopharmaceutical company headquartered in Incheon, South Korea, is merging with its Celltrion Healthcare subsidiary in an effort to strengthen its business synergy or combined effort. The biosimilar producer and its biosimilar marketing unit are set to be consolidated this year.
Seo Jung Jin, Celltrion Group’s chairman, said on Thursday, Aug. 17, that once Celltrion is incorporated with Celltrion Healthcare, the newly-formed entity will also take in Celltrion Pharma. The chairman said this integration will eventually happen later but did not provide an exact time frame. After all the mergings, Celltrion, Celltrion Healthcare, and the company’s chemical pharma producer will work together as one.
According to The Korea Times, Celltrion revealed its plan to acquire Celltrion Healthcare during the company’s recent regulatory filing. The changes will also entail the issuance of new shares of Celltrion to shareholders of Celltrion Healthcare, and the merger ratio is expected to stand at 1:0.4492620.
It was mentioned that the Celltrion chairman holds a 95% stake in Celltrion Holdings which in turn holds a 20.02% stake in Celltrion. The holdings also have a 35.54% stake in Celltrion Healthcare and a 54.96% stake in Celltrion Pharm.
"Celltrion is expected to complete the merger of Celltrion Healthcare by the end of the year, followed by the next merger with Celltrion Pharm in the next six months," Seo Jung Jin shared during an online conference.
The Celltrion Group said it will merge the mentioned companies, but the plan still needs the approval of shareholders. This may be completed on October 23 at the shareholders' meeting. Celltrion and Celltrion Healthcare will eventually be dissolved after the merger.
To date, while the merger is still being processed, The Korea Herald reported that Celltrion is focusing on producing and developing bio-pharmaceutical products while Celltrion Healthcare is working more on selling these products.
Photo by: Celltrion Press Room
